These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 32462921)
1. Roles of angiotensin II as vasopressor in vasodilatory shock. Lumlertgul N; Ostermann M Future Cardiol; 2020 Nov; 16(6):569-583. PubMed ID: 32462921 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin II in Vasodilatory Shock. Wakefield BJ; Busse LW; Khanna AK Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin II in septic shock. Jadhav AP; Sadaka FG Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Agents for the Treatment of Vasodilatory Shock. Knotzer H; Poidinger B; Kleinsasser A Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348 [TBL] [Abstract][Full Text] [Related]
5. THE ROLE OF ANGIOTENSIN -2 IN THE PATHOGENESIS OF SEPTIC SHOCK DURING MULTIORGAN DYSFUNCTION SYNDROME (REVIEW). Rurua M; Machavariani K; Sanikidze T; Shoshiashvili V; Pachkoria E; Ratiani L Georgian Med News; 2022 Feb; (323):157-161. PubMed ID: 35271489 [TBL] [Abstract][Full Text] [Related]
6. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin. Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433 [TBL] [Abstract][Full Text] [Related]
7. Vasopressor therapy in critically ill patients with shock. Russell JA Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370 [TBL] [Abstract][Full Text] [Related]
9. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock. Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial. Bokoch MP; Tran AT; Brinson EL; Marcus SG; Reddy M; Sun E; Roll GR; Pardo M; Fields S; Adelmann D; Kothari RP; Legrand M BMJ Open; 2023 Nov; 13(11):e078713. PubMed ID: 37984940 [TBL] [Abstract][Full Text] [Related]
11. Reversal of Vasodilatory Shock: Current Perspectives on Conventional, Rescue, and Emerging Vasoactive Agents for the Treatment of Shock. Chow JH; Abuelkasem E; Sankova S; Henderson RA; Mazzeffi MA; Tanaka KA Anesth Analg; 2020 Jan; 130(1):15-30. PubMed ID: 31348056 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies. Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515 [TBL] [Abstract][Full Text] [Related]
13. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II (Giapreza): A Distinct Mechanism for the Treatment of Vasodilatory Shock. Khalique SC; Ferguson N Cardiol Rev; 2019; 27(3):167-169. PubMed ID: 30601161 [TBL] [Abstract][Full Text] [Related]
15. Vasopressor Therapy in the Intensive Care Unit. Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475 [TBL] [Abstract][Full Text] [Related]
16. Vasodilatory shock in the ICU and the role of angiotensin II. Wakefield BJ; Sacha GL; Khanna AK Curr Opin Crit Care; 2018 Aug; 24(4):277-285. PubMed ID: 29877879 [TBL] [Abstract][Full Text] [Related]
18. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH; Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690 [TBL] [Abstract][Full Text] [Related]
19. Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. Klijian A; Khanna AK; Reddy VS; Friedman B; Ortoleva J; Evans AS; Panwar R; Kroll S; Greenfeld CR; Chatterjee S J Cardiothorac Vasc Anesth; 2021 Jan; 35(1):51-58. PubMed ID: 32868152 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin II for the Treatment of Vasodilatory Shock. Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM; N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]